Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-low-expressing Breast Cancer|Hormone Receptor-positive Breast Cancer|Neoadjuvant Therapy
Interventions: DRUG: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.